Business Goods & Services

During the serious recession of 2008 and 2009, the healthcare industry was one of the few actual growth areas, just as the USA was in the news due to the president’s intended healthcare reform and the consequent, lengthy delays in Congress. During Pres. Obama’s successful campaign, the healthcare business was much in the news and upon inauguration he pushed both houses of Congress to act quickly and with credibility. It appears as if we are poised on the edge of a momentous change in the industry, which will affect everyone involved from healthcare providers through hospitals, insurance companies and pharmaceutical companies. In these tumultuous times, the role of healthcare and pharmaceutical consulting organisations will be pivotal and all the skills possessed by these companies will be necessary as changes are processed and results analysed.

Healthcare can be seen as a growth industry for a considerable time ahead as the baby boomer generation starts to age and comes to a period when more strain is likely to be placed on the healthcare system. This will call for innovation and the provision of additional services and products by the pharmaceutical company. Competition in the marketplace is sure to evolve.

Costs will be under the microscope in the near future and insurance companies will be torn from both sides, due to their role as the intermediary. Healthcare professionals are sure to receive pressure, as they weigh up the advice that they should give their patients in the light of new rules and rafts of legislation. In short, a period of uncertainty can be expected to add even more pressures to an already pressure packed environment.

In the future, pharmaceutical consultants, already in high demand, will be even more valuable as the role of pharma consulting extends to decipher these new rules and implications. A company’s workforce will benefit from the training provided by these consultants, as they deliver results and draw on years of experience, training and expertise. The parent company’s executives have much to do dealing with the daily concerns and requirements associated with regulatory pressures and production issues. They should devote valuable time to staff administration, maintenance and training. To help ensure that sales executives are deployed correctly and return as high a value as possible to the company, the pharmaceutical consulting firm is ready and willing to take on this important task.

The healthcare business is one of our most dynamic industries and pharmaceutical and healthcare consulting is a critical internal component. Not all organisations interested in the development of a pharmaceutical company can be classified as “friendly” and this puts significant pressures on the company. A pharmaceutical consulting firm is best positioned to advise the company’s executives, by interpreting each position and working out how to approach and handle each party from a position of strength. Make no mistake, there are challenging and risky times ahead, yet these times could also be potentially lucrative and the consultant can be an additional pair of ears and eyes, together with a valued resource. The company is advised to consider a long-term engagement with the pharmaceutical and healthcare consulting firm accordingly.

Alan Gillies is the Managing Director of L2L Consulting, specialising in enabling pharmaceutical companies to achieve new heights of productivity and performance, throughout all levels of management and revenue generating activities.

Be Sociable, Share!

• 

You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.